Install
Empowering Investor Success Morningstar Morningstar is an investment research company offering mutual fund, ETF, and stock analysis, ratings, and data, and portfolio tools. Discover actionable insights today. Plus, whether Nvidia is a buy after earnings.
- 1,388articles · 30d
- 1+ hour agolatest article
- Aug 14, 2026earliest in window
- 88%with images · 6 videos
- 240avg words
- Economy, Business & Finance 752
- Finance & Business 733
- News 416
- Business & Industrial 157
- Finance 151
- Crime, Law & Justice 120
- Health & Wellness 117
- Arts, Culture, Entertainment & Media 115
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
XTIA Investor Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against XTI Aerospace, Inc.
1+ week, 3+ day ago (458+ words) SAN DIEGO, Sept. 2, 2026 SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired XTI Aerospace, Inc. (NASDAQ: XTIA) securities between…...
XTIA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds XTI Aerospace Investors of Securities Class Action Lawsuit Deadline on October 27, 2026
1+ week, 5+ day ago (296+ words) Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in XTI Aerospace to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in XTI Aerospace between April 15, 2026 and August 17, 2026 and would…...
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class Action - Contact SueWallSt
3+ week, 2+ day ago (684+ words) NEW YORK, Aug. 20, 2026 This Regeneron analyst reaction focuses on analysts' reassessment of the Phase III Fianlimab-Libtayo Study after a protocol amendment raised concerns about statistical significance and potential impact on Regeneron's pipeline and future growth expectations. NEW YORK, Aug. 20, 2026 /PRNewswire…...